AELIS FARMA SAS EO -004
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; an… Read more
AELIS FARMA SAS EO -004 (69O) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, AELIS FARMA SAS EO -004 (69O) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
AELIS FARMA SAS EO -004 - Net Assets Trend (None–None)
This chart illustrates how AELIS FARMA SAS EO -004's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AELIS FARMA SAS EO -004 (None–None)
The table below shows the annual net assets of AELIS FARMA SAS EO -004 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to AELIS FARMA SAS EO -004's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
AELIS FARMA SAS EO -004 Competitors by Market Cap
The table below lists competitors of AELIS FARMA SAS EO -004 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Adneo Ltd
AU:AD1
|
$3.91 Million |
|
EQTEC plc
LSE:EQT
|
$3.91 Million |
|
East Asia Holdings Investment Limited
KQ:900110
|
$3.91 Million |
|
Gigasun AB
ST:GIGA
|
$3.91 Million |
|
ENEFI Energiahatekonysagi Nyrt
BUD:ENEFI
|
$3.90 Million |
|
CPanel PCL
BK:CPANEL
|
$3.90 Million |
|
Golden Lime PCL
BK:SUTHA
|
$3.90 Million |
|
Portage Biotech Inc
NASDAQ:PRTG
|
$3.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AELIS FARMA SAS EO -004's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares AELIS FARMA SAS EO -004's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently AELIS FARMA SAS EO -004 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares AELIS FARMA SAS EO -004's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AELIS FARMA SAS EO -004 (69O) | €- | N/A | N/A | $3.91 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |